Patent intelligence · US
US 20260108463
NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION
NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION
Patent details — US 20260108463
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2026
- Expiration
- Apr 18, 2046
- Applicant
- BIOFRONTERA BIOSCIENCE GMBH [DE]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 06 A I, A61K 9/ 107 A I, A61K 31/ 436 A I
Quick answer
US 20260108463 (NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION) is held by BIOFRONTERA BIOSCIENCE GMBH [DE]. Status: granted. Granted Apr 23, 2026. Expires Apr 18, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOFRONTERA BIOSCIENCE GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 06 A I, A61K 9/ 107 A I, A61K 31/ 436 A I, A61K 47/ 10 A I, A61K 47/ 14 A I
More from BIOFRONTERA BIOSCIENCE GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
US 2024335360
PRESSURIZED NANOEMULSION
granted -
WO 2024209065
NANOÉMULSION SOUS PRESSION
granted -
WO 2024209064
NANOÉMULSION SANS PROPYLÈNE GLYCOL
granted -
US 2024335380
NANOEMULSION WITHOUT PROPYLENE GLYCOL
granted -
US 2021315993
PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS
granted -
WO 2014117863
FORMES POLYMORPHES DE SELS D'ADDITION D'ACIDE DE THIOXANTHÈNE-9-YLIDÈNE-1-MÉTHYLPIPÉRIDINES UTILISÉS COMME COMPOSÉS ANTIMIGRAINEUX
granted -
DE 202010004750
Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
granted
Frequently asked questions
What is US patent 20260108463?
US 20260108463 (NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION) is held by BIOFRONTERA BIOSCIENCE GMBH [DE]. Status: granted. Granted Apr 23, 2026. Expires Apr 18, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 20260108463?
BIOFRONTERA BIOSCIENCE GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 20260108463 expire?
Our index shows an expiration date of Apr 18, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.